The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
SOPHARMA AD (the “Company”) hereby informs that from 3 July 2014 up to and including 9 July 2014 the Company bought 1 277 own shares representing 0.001% of the share capital of the Company, to the total value of 5 512.97 BGN on the Bulgarian Stock Exchange, the average price per share was 4.32 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 4 999 925, representing 3.79% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 10 July 2014 up to and including 16 July 2014 the Company bought 24 177 own shares representing 0.018% of the share capital of the Company, to the total value of 99 990.82 BGN on the Bulgarian Stock Exchange, the average price per share was 4.14 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 024 102, representing 3.81% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 17 July 2014 up to and including 23 July 2014 the Company bought 6 476 own shares representing 0.005% of the share capital of the Company, to the total value of 26 747.69 BGN on the Bulgarian Stock Exchange, the average price per share was 4.13 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 030 578, representing 3.81% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 24 July 2014 up to and including 30 July 2014 the Company bought 16 450 own shares representing 0.012% of the share capital of the Company, to the total value of 68 247.25 BGN on the Bulgarian Stock Exchange, the average price per share was 4.15 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 047 028, representing 3.82% of the share capital of the Company.
Sopharma AD (the “Company”) notifies that for July 2014 the Company recorded an increase of sales revenues of 7% compared to the same period of 2013, including 2% increase of domestic sales and 16% increase of export sales.
During the past seven months Sopharma AD recorded a decrease of sales revenues of 4%, including 2% increase of domestic sales and 7% decrease of export sales compared to 2013.
SOPHARMA AD (the “Company”) hereby informs that from 31 July 2014 up to and including 6 August 2014 the Company bought 14 606 own shares representing 0.011% of the share capital of the Company, to the total value of 61 172.17BGN on the Bulgarian Stock Exchange, the average price per share was 4.19 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 061 634, representing 3.83% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 07 August 2014 up to and including 13 August 2014 the Company bought 3 468 own shares representing 0.0026% of the share capital of the Company, to the total value of 14 632.56 BGN on the Bulgarian Stock Exchange, the average price per share was 4.22 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 065 102, representing 3.84 % of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 14 August 2014 up to and including 20 August 2014 the Company bought 773 own shares representing 0.0006% of the share capital of the Company, to the total value of 3 261.40 BGN on the Bulgarian Stock Exchange, the average price per share was 4.22 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 065 875, representing 3.84 % of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 21 August 2014 up to and including 27 August 2014 the Company bought 1 280 own shares representing 0.00097% of the share capital of the Company, to the total value of 5 400.92 BGN on the Bulgarian Stock Exchange, the average price per share was 4.219 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 067 155, representing 3.84% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 28 August 2014 up to and including 3 September 2014 the Company bought 4900 own shares representing 0.0037% of the share capital of the Company, to the total value of 20 687.8 BGN on the Bulgarian Stock Exchange, the average price per share was 4.222 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 072 055, representing 3.84% of the share capital of the Company.